D-0939-2023 Class II Terminated

Recalled by Glenmark Therapeutics, Inc. — Mahwah, NJ

FDA drug recall D-0939-2023 was initiated by Glenmark Therapeutics, Inc. on May 1, 2023 and is designated Class II. Reason for recall: Labeling: Label Error on Declared Strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg. The recall status is terminated (terminated Sep 17, 2024). Affected quantity: 19,968 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 26, 2023
Initiation Date
May 1, 2023
Termination Date
Sep 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
19,968 bottles

Product description

Famotidine Tablets, USP, 20mg, 200-count bottle within a carton, Distributed by: Glenmark Therapeutics Inc., USA, Mahwah, NJ 07430, Made in India, NDC 72657-113-20.

Reason for recall

Labeling: Label Error on Declared Strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg.

Distribution pattern

Nationwide in the USA

Code information

FA2022001B, Exp 03/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0939-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0939-2023. Report a data issue: hello@regdatalab.com.